{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:25:09Z","timestamp":1794306309503,"version":"4.9.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100003064","name":"Kidney Cancer Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08CA234392"],"award-info":[{"award-number":["K08CA234392"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012287","name":"Andrew Sabin Family Foundation","doi-asserted-by":"publisher","award":["KC200096P1"],"award-info":[{"award-number":["KC200096P1"]}],"id":[{"id":"10.13039\/100012287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016957","name":"Mirati Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001634","name":"Gateway for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002163","name":"Johnson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002163","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.euo.2023.12.001","type":"journal-article","created":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T15:08:04Z","timestamp":1702739284000},"page":"933-943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-8308","authenticated-orcid":false,"given":"Pavlos","family":"Msaouel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy F.","family":"Sweis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manojkumar","family":"Bupathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Oscar B.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Hoimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew I.","family":"Milowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash Rezazadeh","family":"Kalebasty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Picus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifeng","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Adra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Yorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Siefker-Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Latven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis D.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirak","family":"Der-Torossian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Mortazavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopa","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2023.12.001_b0005","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.21037\/tau-20-1177","article-title":"Combination therapies involving checkpoint-inhibitors for treatment of urothelial carcinoma: a narrative review","volume":"10","author":"Schulz","year":"2021","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.euo.2023.12.001_b0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.12.001_b0015","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.12.001_b0020","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2023.12.001_b0025","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.euo.2023.12.001_b0030","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41422-020-0337-2","article-title":"The future of cancer immunotherapy: microenvironment-targeting combinations","volume":"30","author":"Murciano-Goroff","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.euo.2023.12.001_b0035","doi-asserted-by":"crossref","first-page":"e124184","DOI":"10.1172\/jci.insight.124184","article-title":"Sitravatinib potentiates immune checkpoint blockade in refractory cancer models","volume":"3","author":"Du","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.euo.2023.12.001_b0040","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/14728222.2021.1869212","article-title":"TAM kinase inhibition and immune checkpoint blockade\u2013a winning combination in cancer treatment?","volume":"25","author":"Msaouel","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.euo.2023.12.001_b0045","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/imr.12522","article-title":"TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy","volume":"276","author":"Akalu","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.euo.2023.12.001_b0050","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrc3847","article-title":"The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer","volume":"14","author":"Graham","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.euo.2023.12.001_b0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/cancers8100097","article-title":"The role of TAM family receptors in immune cell function: implications for cancer therapy","volume":"8","author":"Paolino","year":"2016","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euo.2023.12.001_b0060","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12935-021-02089-2","article-title":"New insights into M1\/M2 macrophages: key modulators in cancer progression","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.euo.2023.12.001_b0065","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2023.12.001_b0070","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1038\/s41467-023-38342-7","article-title":"Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma","volume":"14","author":"Karam","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2023.12.001_b0075","doi-asserted-by":"crossref","first-page":"eabm6420","DOI":"10.1126\/scitranslmed.abm6420","article-title":"A phase 1\u20132 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy","volume":"14","author":"Msaouel","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.euo.2023.12.001_b0080","unstructured":"EMD Serono, Inc. BAVENCIO prescribing information. https:\/\/www.emdserono.com\/us-en\/pi\/bavencio-pi.pdf."},{"key":"10.1016\/j.euo.2023.12.001_b0085","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1200\/JCO.2023.41.6_suppl.518","article-title":"Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy","volume":"41","author":"Grivas","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.12.001_b0090","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2023.12.001_b0095","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1158\/1078-0432.CCR-21-3726","article-title":"Cabozantinib plus nivolumab phase I expansion study in patients with metastatic urothelial carcinoma refractory to immune checkpoint inhibitor therapy","volume":"28","author":"Girardi","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2023.12.001_b0100","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clgc.2022.11.003","article-title":"Treatment rechallenge with immune checkpoint inhibitors in advanced urothelial carcinoma","volume":"21","author":"Makrakis","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2023.12.001_b0105","unstructured":"Agensys, Inc and Seattle Genetics, Inc. PADCEV prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761137s018.pdf."},{"key":"10.1016\/j.euo.2023.12.001_b0110","unstructured":"Janssen Pharmaceutical Companies. BALVERSA prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212018s000lbl.pdf."},{"key":"10.1016\/j.euo.2023.12.001_b0115","unstructured":"Immunomedics, Inc. TRODELVY prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761115s000lbl.pdf."}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931123002821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931123002821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:35:01Z","timestamp":1794303301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931123002821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2588931123002821"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2023.12.001","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2023.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}